Gilead Sciences's EBIT per Share for the
three
months ended in Dec. 2023 was $1.52.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $6.21.
During the past 12 months, the average EBIT per Share Growth Rate of Gilead Sciences was -19.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -3.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 1.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Gilead Sciences's EBIT per Share or its related term are showing as below:
GILD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -47.7 Med: 5.9 Max: 128.6
Current: -3.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Gilead Sciences was 128.60% per year. The lowest was -47.70% per year. And the median was 5.90% per year.
GILD's 3-Year EBIT Growth Rate is ranked worse than 67.84% of 852
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs GILD: -3.80
Gilead Sciences's EBIT for the
three
months ended in Dec. 2023 was $1,905 Mil.
Gilead Sciences EBIT per Share Historical Data
The historical data trend for Gilead Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (NAS:GILD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Gilead Sciences EBIT per Share Related Terms
Thank you for viewing the detailed overview of Gilead Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences (Gilead Sciences) Business Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GILD has been successfully added to your 